U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940440) titled 'IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)' on April 03.
Brief Summary: This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (>=18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Advanced Or Metastatic Merkel Cell Carcinoma
Intervention:
DRUG: IFx-Hu2.0
Therapeutic Classification:
* Inna...